NO314533B1 - Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes - Google Patents
Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes Download PDFInfo
- Publication number
- NO314533B1 NO314533B1 NO19951596A NO951596A NO314533B1 NO 314533 B1 NO314533 B1 NO 314533B1 NO 19951596 A NO19951596 A NO 19951596A NO 951596 A NO951596 A NO 951596A NO 314533 B1 NO314533 B1 NO 314533B1
- Authority
- NO
- Norway
- Prior art keywords
- toremifene
- treatment
- lpr
- mice
- acceptable salt
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 10
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 title claims description 15
- 229960005026 toremifene Drugs 0.000 title claims description 14
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims description 10
- 239000003814 drug Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 10
- 229940046836 anti-estrogen Drugs 0.000 abstract description 10
- 230000001833 anti-estrogenic effect Effects 0.000 abstract description 10
- 239000000328 estrogen antagonist Substances 0.000 abstract description 10
- 239000003862 glucocorticoid Substances 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 8
- 241000699670 Mus sp. Species 0.000 description 28
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 22
- 229960004167 toremifene citrate Drugs 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 206010018364 Glomerulonephritis Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000003637 steroidlike Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229960005205 prednisolone Drugs 0.000 description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 6
- 206010040628 Sialoadenitis Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 208000001050 sialadenitis Diseases 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108010052621 fas Receptor Proteins 0.000 description 3
- 102000018823 fas Receptor Human genes 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- SBVVUEPVKSOHHY-UHFFFAOYSA-N n,n-dimethyl-1-phenoxyethanamine Chemical compound CN(C)C(C)OC1=CC=CC=C1 SBVVUEPVKSOHHY-UHFFFAOYSA-N 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31077292 | 1992-10-27 | ||
| PCT/JP1993/001543 WO1994009764A1 (en) | 1992-10-27 | 1993-10-26 | Use of non steroidal anti estrogens for autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO951596L NO951596L (no) | 1995-04-26 |
| NO951596D0 NO951596D0 (no) | 1995-04-26 |
| NO314533B1 true NO314533B1 (no) | 2003-04-07 |
Family
ID=18009292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19951596A NO314533B1 (no) | 1992-10-27 | 1995-04-26 | Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes |
| NO20025179A NO317544B1 (no) | 1992-10-27 | 2002-10-28 | Produkter for autoimmune sykdommer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025179A NO317544B1 (no) | 1992-10-27 | 2002-10-28 | Produkter for autoimmune sykdommer |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6355688B1 (de) |
| EP (2) | EP0667768B1 (de) |
| KR (1) | KR100303634B1 (de) |
| CN (1) | CN1053337C (de) |
| AT (1) | ATE177008T1 (de) |
| AU (1) | AU5286693A (de) |
| DE (1) | DE69323759T2 (de) |
| DK (1) | DK0667768T3 (de) |
| ES (1) | ES2128441T3 (de) |
| GR (1) | GR3029682T3 (de) |
| NO (2) | NO314533B1 (de) |
| WO (1) | WO1994009764A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69435137D1 (de) * | 1993-05-13 | 2008-10-16 | Poniard Pharmaceuticals Inc | Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind |
| US5521198A (en) | 1993-12-21 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting autoimmune diseases |
| JP2001511182A (ja) * | 1997-02-09 | 2001-08-07 | ファーモス コーポレイション | ステロイドホルモンの永久に荷電された誘導体の増進された抗血管形成誘導活性 |
| EP1018058A2 (de) | 1997-03-06 | 2000-07-12 | Nashua Corporation | Verbesserte anzeige |
| BR0013272B1 (pt) | 1999-08-13 | 2013-10-15 | Uso de um inibidor de aromatase esteroidal | |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| US7069444B2 (en) * | 2002-01-25 | 2006-06-27 | Brent A. Lowensohn | Portable wireless access to computer-based systems |
| WO2009149081A1 (en) * | 2008-06-02 | 2009-12-10 | Novelmed Therapeutics, Inc. | Method for treating inflammatory conditions |
| EP2393728B1 (de) | 2009-02-09 | 2014-09-17 | Valspar Sourcing, Inc. | Nicht-infrarot-absorbierendes färb- und bedruckungssystem für geschäfte |
| ES2675093T3 (es) | 2009-02-09 | 2018-07-06 | Valspar Sourcing, Inc. | Sistema de pintura y tintura no absorbentes de los infrarrojos y teñibles en tienda |
| CN103154154B (zh) | 2010-07-01 | 2016-02-17 | 威士伯采购公司 | 红外反射性双组份涂料组合物 |
| CN102942827A (zh) | 2010-10-20 | 2013-02-27 | 威士伯采购公司 | 具有改善耐湿性和耐热性的水基涂料体系 |
| RU2572504C1 (ru) * | 2013-12-26 | 2016-01-10 | Андрей Константинович Иорданишвили | Способ лечения лучевой сиалоаденопатии |
| EP3420024A4 (de) | 2016-02-23 | 2020-02-19 | Advanced Environmental Recycling Technologies, Inc | Zusammensetzungen und verfahren zur verringerung der oberflächentemperatur von verbundartikeln |
| EP3562682A1 (de) | 2017-01-01 | 2019-11-06 | Advanced Environmental Recycling Technologies, Inc | Verfahren zur beschichtung von verbundartikeln |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU172948B (hu) | 1976-02-05 | 1979-01-28 | Gyogyszerkutato Intezet | Sposob poluchenija osnovnykh proizvodnykh trifenil-alkenov |
| DE2860900D1 (en) | 1977-08-22 | 1981-11-05 | Ici Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
| DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| FI67538C (fi) | 1982-05-27 | 1985-04-10 | Farmos Oy | Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten |
| GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| US5348729A (en) * | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| US4990538A (en) | 1989-08-23 | 1991-02-05 | Harris Adrian L | Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs |
| JPH04312526A (ja) * | 1991-04-09 | 1992-11-04 | Fujisawa Pharmaceut Co Ltd | 骨疾患治療剤 |
-
1993
- 1993-10-26 AU AU52866/93A patent/AU5286693A/en not_active Abandoned
- 1993-10-26 DK DK93923058T patent/DK0667768T3/da active
- 1993-10-26 EP EP93923058A patent/EP0667768B1/de not_active Expired - Lifetime
- 1993-10-26 AT AT93923058T patent/ATE177008T1/de not_active IP Right Cessation
- 1993-10-26 EP EP96119031A patent/EP0776661A1/de not_active Withdrawn
- 1993-10-26 DE DE69323759T patent/DE69323759T2/de not_active Expired - Fee Related
- 1993-10-26 WO PCT/JP1993/001543 patent/WO1994009764A1/en active IP Right Grant
- 1993-10-26 KR KR1019930022299A patent/KR100303634B1/ko not_active IP Right Cessation
- 1993-10-26 ES ES93923058T patent/ES2128441T3/es not_active Expired - Lifetime
- 1993-10-27 CN CN93120398A patent/CN1053337C/zh not_active Expired - Fee Related
-
1995
- 1995-04-26 NO NO19951596A patent/NO314533B1/no unknown
-
1999
- 1999-03-12 GR GR990400766T patent/GR3029682T3/el unknown
-
2000
- 2000-03-01 US US09/516,435 patent/US6355688B1/en not_active Expired - Fee Related
-
2001
- 2001-07-16 US US09/906,169 patent/US6387958B1/en not_active Expired - Fee Related
-
2002
- 2002-01-10 US US10/044,064 patent/US6458848B1/en not_active Expired - Fee Related
- 2002-10-28 NO NO20025179A patent/NO317544B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0667768B1 (de) | 1999-03-03 |
| NO951596L (no) | 1995-04-26 |
| US6458848B1 (en) | 2002-10-01 |
| ATE177008T1 (de) | 1999-03-15 |
| US20020107231A1 (en) | 2002-08-08 |
| NO20025179L (no) | 1995-04-26 |
| KR100303634B1 (ko) | 2001-11-22 |
| US6355688B1 (en) | 2002-03-12 |
| NO951596D0 (no) | 1995-04-26 |
| AU5286693A (en) | 1994-05-24 |
| DE69323759T2 (de) | 1999-07-22 |
| NO317544B1 (no) | 2004-11-08 |
| NO20025179D0 (no) | 2002-10-28 |
| WO1994009764A1 (en) | 1994-05-11 |
| GR3029682T3 (en) | 1999-06-30 |
| CN1053337C (zh) | 2000-06-14 |
| CN1100930A (zh) | 1995-04-05 |
| EP0776661A1 (de) | 1997-06-04 |
| US6387958B1 (en) | 2002-05-14 |
| DK0667768T3 (da) | 1999-09-27 |
| DE69323759D1 (de) | 1999-04-08 |
| EP0667768A1 (de) | 1995-08-23 |
| ES2128441T3 (es) | 1999-05-16 |
| KR940008677A (ko) | 1994-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO314533B1 (no) | Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes | |
| Trentham et al. | Relapsing polychondritis | |
| TWI389683B (zh) | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient | |
| JPH05507697A (ja) | 臓器移植拒絶反応の治療 | |
| CA2640484A1 (en) | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith | |
| CN1984654A (zh) | 抗－hiv逆转录酶和蛋白酶抑制剂的组合 | |
| Linton et al. | Methods of forced diuresis and its application in barbiturate poisoning | |
| Marigold et al. | Propranolol, oxprenolol, and sclerosing peritonitis. | |
| JP2017525719A (ja) | 関節リウマチの治療における１つの丸剤・錠剤・カプセル剤でのミノサイクリン、アシクログアノシン、アトルバスタチンおよびビタミンｄの使用 | |
| RU2322238C2 (ru) | Лечение ревматоидного артрита | |
| US5886049A (en) | Remedy for autoimmune diseases | |
| CA2148006C (en) | Use of non-steroidal antiestrogens for autoimmune diseases | |
| JPS624229A (ja) | 鎮痛及び消炎作用を有する医薬 | |
| JP3566741B2 (ja) | 自己免疫疾患治療薬 | |
| TW201505635A (zh) | 治療潰瘍性結腸炎之方法 | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| Ofili | Possibilities of the strong posterior wall of inguinal canal in women | |
| US20080319073A1 (en) | Colonic delivery therapeutic agents for inflammatory bowel disease | |
| EP1786438A1 (de) | Verfahren zur erhöhung der mineralischen knochendichte und der knochenmikroarchitektur oder konnektivität eines säugetiers mit n-acylierten glucosaminen | |
| US20100144873A1 (en) | Treatment of myocarditis using fts | |
| CA2569479A1 (en) | Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| WO2024172001A1 (ja) | 抗トリパノソーマ薬 | |
| Wakefield et al. | Investigation and management of scleritis | |
| JP2023548788A (ja) | 胆汁うっ滞性そう痒症を治療する方法 | |
| WO2024015067A1 (en) | Methods of administering belumosudil for treatment of chronic graft versus host disease |